ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 174 filers reported holding ASCENDIS PHARMA A/S in Q2 2021. The put-call ratio across all filers is 4.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $36,432 | -19.1% | 241 | -49.9% | 0.00% | -33.3% |
Q3 2023 | $45,041 | +4.9% | 481 | 0.0% | 0.01% | +20.0% |
Q2 2023 | $42,929 | -16.8% | 481 | 0.0% | 0.01% | -28.6% |
Q1 2023 | $51,573 | -12.2% | 481 | 0.0% | 0.01% | 0.0% |
Q4 2022 | $58,745 | +19.9% | 481 | 0.0% | 0.01% | -12.5% |
Q3 2022 | $49,000 | -12.5% | 481 | 0.0% | 0.01% | +14.3% |
Q1 2022 | $56,000 | -13.8% | 481 | 0.0% | 0.01% | -12.5% |
Q4 2021 | $65,000 | -15.6% | 481 | 0.0% | 0.01% | -11.1% |
Q3 2021 | $77,000 | -38.9% | 481 | -49.9% | 0.01% | -47.1% |
Q2 2021 | $126,000 | +1.6% | 961 | 0.0% | 0.02% | -22.7% |
Q1 2021 | $124,000 | -12.7% | 961 | 0.0% | 0.02% | -37.1% |
Q2 2020 | $142,000 | +31.5% | 961 | 0.0% | 0.04% | +16.7% |
Q1 2020 | $108,000 | -1.8% | 961 | 0.0% | 0.03% | +3.4% |
Q2 2019 | $110,000 | -2.7% | 961 | 0.0% | 0.03% | -6.5% |
Q1 2019 | $113,000 | – | 961 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |